Cyclic Peptide Cocrystallization Without Column Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of methods for producing cocrystals of cyclic peptides, particularly those containing N-substituted amino acids, and existing methods for screening and isolating such crystals are inefficient, particularly in obtaining specific compounds and specific solvent systems.
Innovation Solution
A method involving bringing a cyclic peptide into contact with a specific compound and a solvent to efficiently produce a cocrystal, utilizing compounds with a molecular weight of 500 g/mol or less, preferably 400 or less, and specific solvents such as amides, alcohols, and ketones, without the need for column chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If cyclic peptides are crystallized using conventional methods, then crystal forms can be obtained, but the process is complex and requires column chromatography which reduces productivity
Solution Approach 1:
The patent introduces cocrystal formation as an intermediary approach that simplifies the crystallization process. By forming cocrystals with suitable coformers, the method avoids complex column chromatography while efficiently obtaining pure cyclic peptide crystals, thus resolving the contradiction between process simplicity and productivity
Solution Approach 2:
The patent changes the crystallization parameters by using cocrystal formation conditions (specific solvents, temperatures, and coformers) instead of conventional purification methods. This parameter change enables direct crystal obtention without column chromatography, improving both ease of manufacture and productivity
2Reliability
If cyclic peptides containing N-substituted amino acids are used to improve metabolic stability and membrane permeability, then drug-likeness is enhanced, but crystallization becomes more difficult
Solution Approach 1:
The patent creates composite crystal structures (cocrystals) combining cyclic peptides with suitable coformers. This composite approach maintains the metabolic stability benefits of N-substituted amino acids while the cocrystal lattice facilitates easier crystallization and purification
Solution Approach 2:
Coformers act as intermediaries that mediate the crystallization process of difficult-to-crystallize cyclic peptides containing N-substituted amino acids. The coformers facilitate crystal lattice formation without interfering with the metabolic stability properties of the peptide
3Ease of operation
If conventional small molecule compounds are used, then oral drug development is feasible, but they cannot effectively inhibit protein-protein interactions at target surfaces
Solution Approach 1:
The patent applies local quality modification by introducing N-substituted amino acids at specific positions within the cyclic peptide structure. This localized modification enhances the peptide's ability to inhibit protein-protein interactions while maintaining overall drug-like properties suitable for oral administration
Solution Approach 2:
The patent changes molecular parameters by transitioning from conventional small molecules to middle molecule cyclic peptides with molecular weights above 500 g/mol. This parameter change enables effective protein-protein interaction inhibition while maintaining oral drug feasibility through optimized cyclic peptide design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the production of cocrystals of cyclic peptides, enhancing metabolic stability and membrane permeability, and providing a simple and efficient way to screen and isolate these compounds.
Implementation Method 1
A method for producing a cocrystal of a cyclic peptide
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method for producing a cocrystal containing a cyclic peptide and a compound with a melting point of 20°C or higher, the method comprising a step of bringing the cyclic peptide into contact with the compound and a solvent.